Renascience

Renascience Equity Growth

The Year-over-Year Equity Growth of Renascience (4889.T) as of Nov 19, 2026 is 93.16 %. In the previous year, Year-over-Year Equity Growth was 7.06 % — a change of 1,219.66% (higher).

Equity Growth

93.16 %

YoY

1,219.66%

Last updated:

Year-over-Year Equity Growth of Renascience is 2026 93.16 % . Year-over-Year Equity Growth of Renascience was 2025 7.06 % . It decreases by 1,219.66% higher compared to the previous year.

The Renascience Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2021
-9.66 JPY
Jan 1, 2022
291.94 JPY
Jan 1, 2023
-15.26 JPY
Jan 1, 2024
-13.85 JPY
Jan 1, 2025
7.06 JPY
Jan 1, 2026
93.16 JPY
The Renascience Equity Growth history
YEAREquity GrowthYoY
93.16 %+1,219.66%
7.06 %-150.97%
-13.85 %-9.22%
-15.26 %-105.23%
291.94 %-3,121.69%
-9.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Year-over-Year Equity Growth of Renascience is 93.16 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Renascience since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Renascience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Renascience

All Key Metrics — Renascience